bioMerieux (OTCMKTS:BMXMF) and Amplifon (OTCMKTS:AMFPF) Head-To-Head Review

bioMerieux (OTCMKTS:BMXMF) and Amplifon (OTCMKTS:AMFPF) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for bioMerieux and Amplifon, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioMerieux	0	5	0	0	2.00
Amplifon	0	2	2	0	2.50

Volatility and Risk

bioMerieux has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Amplifon has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Profitability

This table compares bioMerieux and Amplifon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioMerieux	N/A	N/A	N/A
Amplifon	2.87%	16.04%	4.20%

Valuation and Earnings

This table compares bioMerieux and Amplifon”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioMerieux	$4.60 billion	2.01	$449.73 million	N/A	N/A
Amplifon	$2.71 billion	0.97	$103.33 million	$0.36	33.36

bioMerieux has higher revenue and earnings than Amplifon.

Summary

Amplifon beats bioMerieux on 5 of the 9 factors compared between the two stocks.

About bioMerieux

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

About Amplifon

Amplifon S.p.A. engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Ampli-easy, Ampli-connect, Ampli-energy, and Ampli-mini hearing devices. It also operates Ampli-care, a platform to deliver audiological care experience; and Amplifon App to manage the device functions in real-time directly from smartphone. Amplifon S.p.A. was founded in 1950 and is headquartered in Milan, Italy. Amplifon S.p.A.